{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T19:49:06Z","timestamp":1771616946335,"version":"3.50.1"},"reference-count":52,"publisher":"Informa UK Limited","issue":"7","funder":[{"name":"MSD, Pfizer and Viiv Healthcare"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.2217\/fmb-2020-0012","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T12:26:21Z","timestamp":1587126381000},"page":"473-484","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":31,"title":["Update on the Role of Ceftazidime-Avibactam in the Management of Carbapenemase-Producing Enterobacterales"],"prefix":"10.1080","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6011-6986","authenticated-orcid":false,"given":"Beatriz","family":"Dietl","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit. Internal Medicine Department,Hospital Universitari M\u00fatua de Terrassa,\rBarcelona,\rSpain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Pharmacy Department,Hospital Universitari M\u00fatua de Terrassa,\rBarcelona,\rSpain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Calbo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit. Internal Medicine Department,Hospital Universitari M\u00fatua de Terrassa,\rBarcelona,\rSpain"},{"name":"Department of Medicine,Faculty of Medicine & Health Science,Universitat Internacional de Catalunya,\rBarcelona,\rSpain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Garau","sequence":"additional","affiliation":[{"name":"Head of Internal Medicine Department,Clinica Rotger,\rPalma de Mallorca\rSpain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,4,17]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2015.01.008"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03821.x"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw282"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70041-0"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30605-4"},{"key":"e_1_3_3_8_1","unstructured":"World Health Organization (2018). https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Antimicrobial-consumption-EU-EEA.pdf"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1205073109"},{"key":"e_1_3_3_10_1","unstructured":"Zavicefta EPAR public assessment report. https:\/\/www.ema.europa.eu\/en\/medicines\/uman\/epar\/zavicefta"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.748653"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw243"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0283-9"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv170"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm325"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1622"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks523"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.793"},{"key":"e_1_3_3_19_1","article-title":"PK\/PD target attainment analyses and assessment of dose adjustments for renal insufficiency for ceftazidime-avibactam (CAZ-AVI) in patients with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) or nosocomial pneumonia","author":"Li J","year":"2015","unstructured":"Li J , ZhouD, DasS, LovernM, WadaR, BellantiF. PK\/PD target attainment analyses and assessment of dose adjustments for renal insufficiency for ceftazidime-avibactam (CAZ-AVI) in patients with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) or nosocomial pneumonia. Am. Assoc. Pharm. Sci. (AAPS) Anual Meeting and Exposition (2015).","journal-title":"Am. Assoc. Pharm. Sci. (AAPS) Anual Meeting and Exposition"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30747-8"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00464-17"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw378"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30004-4"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw133"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.01.010"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.01.018"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw636"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01964-16"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz522"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky295"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.11.015"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00883-17"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix783"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy492"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02320-19"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2017.03.021"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy576"},{"key":"e_1_3_3_38_1","article-title":"Assessment of MIC increases with meropenem-vaborbactam and ceftazidime-avibactam in TANGOII (a Phase III study of the treatment of CRE infections)","author":"Lomovskaya O","year":"2017","unstructured":"Lomovskaya O , CastanheiraM, V\u00e1zquezJ, KayeK, NelsonK, SunD. Assessment of MIC increases with meropenem-vaborbactam and ceftazidime-avibactam in TANGOII (a Phase III study of the treatment of CRE infections). ID Week (2017).","journal-title":"ID Week"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02497-17"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.11.011"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12585"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02187-18"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0705-y"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2016.1221021"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu027"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1881-1889.2005"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2016.48.2.81"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.10.021"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.06.002"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks468"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.12.009"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw272"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02283-13"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.11.014"}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb-2020-0012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:38:54Z","timestamp":1719124734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb-2020-0012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,17]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.2217\/fmb-2020-0012"],"URL":"https:\/\/doi.org\/10.2217\/fmb-2020-0012","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}